David P. Southwell - 31 Mar 2023 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
31 Mar 2023
Net transactions value
-$128,672
Form type
4
Filing time
04 Apr 2023, 16:07:03 UTC
Previous filing
29 Mar 2023
Next filing
19 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $46,304 +2,571 +24% $18.01 13,071 31 Mar 2023 Direct F1
transaction PTCT Common Stock Sale $128,672 -2,571 -20% $50.05 10,500 31 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise $46,304 -2,571 -18% $18.01 11,429 31 Mar 2023 Common Stock 2,571 $18.01 Direct F1, F3
holding PTCT Stock Option (Right to Buy) 12,000 31 Mar 2023 Common Stock 12,000 $51.00 Direct F3
holding PTCT Stock Option (Right to Buy) 12,000 31 Mar 2023 Common Stock 12,000 $30.86 Direct F3
holding PTCT Stock Option (Right to Buy) 14,000 31 Mar 2023 Common Stock 14,000 $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 10,000 31 Mar 2023 Common Stock 10,000 $51.16 Direct F3
holding PTCT Stock Option (Right to Buy) 10,000 31 Mar 2023 Common Stock 10,000 $66.49 Direct F3
holding PTCT Stock Option (Right to Buy) 12,000 31 Mar 2023 Common Stock 12,000 $38.10 Direct F3
holding PTCT Stock Option (Right to Buy) 10,000 31 Mar 2023 Common Stock 10,000 $39.42 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Currently exercisable.
F4 This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023.